ELIZABETH LANGLOIS: Open Payments
NPI 1215660485 · LAFAYETTE, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$865 in 44 payments from 25 companies in 2025. Trend: 2023 $888 · 2024 $1,114 · 2025 $865
Food & beverage: $865
| Company | Payments | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC | 4 | $88 |
| AstraZeneca Pharmaceuticals LP | 4 | $64 |
| Janssen Biotech, Inc. | 3 | $58 |
| Celgene Corporation | 3 | $54 |
| ABBVIE INC. | 3 | $51 |
| Daiichi Sankyo Inc. | 2 | $48 |
| Eisai Inc. | 2 | $44 |
| Novartis Pharmaceuticals Corporation | 2 | $43 |
| GlaxoSmithKline, LLC. | 2 | $39 |
| PFIZER INC. | 2 | $37 |
Products named: REBLOZYL, KEYTRUDA, Enhertu, Lenvima, SARCLISA, LYNPARZA, ZIIHERA, TALVEY.
Industry payments across LA — which companies pay providers there.
